Gaffney Kelly J, Dahl Elizabeth M, Stanton Michael P, Starek Elizabeth, Zembillas Anthony S
J Pediatr Pharmacol Ther. 2020;25(3):215-219. doi: 10.5863/1551-6776-25.3.215.
The use of rapid rituximab infusion in certain pediatric populations has generally been regarded as safe. The safety of our institution's rapid rituximab protocol was evaluated.
The primary end point was the number of and severity of adverse drug reactions. Secondary end points included a description of the patient population defined by the indication, dose, and number of rituximab infusions administered. Additionally, the difference in infusion times in hours of those receiving rapid rituximab infusions versus the theoretical infusion time of subsequent administration rate schedules was defined.
A total of 88 infusions for 22 patients were reviewed. No dose-limiting adverse reactions were observed. Three patients experienced grade 1 isolated infusion-related adverse events during a single infusion encounter. Two of the three patients received additional doses of rapid rituximab infusions without incident, whereas the other patient no longer required rituximab therapy.
The use of a 90-minute rituximab infusion protocol in pediatric patients with non-rheumatic diseases was well tolerated.
在某些儿科人群中快速输注利妥昔单抗通常被认为是安全的。我们评估了本机构快速利妥昔单抗方案的安全性。
主要终点是药物不良反应的数量和严重程度。次要终点包括根据利妥昔单抗输注的适应症、剂量和次数确定的患者人群描述。此外，还确定了接受快速利妥昔单抗输注的患者与后续给药速率方案的理论输注时间相比在输注时间（小时）上的差异。
共审查了22例患者的88次输注。未观察到剂量限制性不良反应。3例患者在单次输注过程中发生1级孤立的输注相关不良事件。3例患者中有2例接受了额外剂量的快速利妥昔单抗输注且未发生不良事件，而另1例患者不再需要利妥昔单抗治疗。
在患有非风湿性疾病的儿科患者中使用90分钟利妥昔单抗输注方案耐受性良好。
